FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212 | -55.5% | 100 | 0.0% | 0.00% | – |
| Q2 2023 | $476 | -16.5% | 100 | 0.0% | 0.00% | – |
| Q1 2023 | $570 | -43.5% | 100 | 0.0% | 0.00% | – |
| Q4 2022 | $1,009 | -90.8% | 100 | -78.7% | 0.00% | -100.0% |
| Q3 2022 | $11,000 | -8.3% | 470 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $12,000 | -33.3% | 470 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $18,000 | -33.3% | 470 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $27,000 | -3.6% | 470 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $28,000 | -31.7% | 470 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $41,000 | +5.1% | 470 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $39,000 | -25.0% | 470 | -17.5% | 0.00% | -25.0% |
| Q4 2020 | $52,000 | +333.3% | 570 | +83.9% | 0.00% | +300.0% |
| Q3 2020 | $12,000 | +9.1% | 310 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $11,000 | +57.1% | 310 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $7,000 | – | 310 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $83,733,000 | 21.39% |
| Redmile Group, LLC | 12,957,222 | $321,080,000 | 12.26% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $25,703,000 | 5.81% |
| Casdin Capital, LLC | 2,100,000 | $52,038,000 | 4.40% |
| Ally Bridge Group (NY) LLC | 181,500 | $4,498,000 | 4.10% |
| DAFNA Capital Management LLC | 550,940 | $13,652,000 | 3.72% |
| Artal Group S.A. | 2,600,000 | $64,428,000 | 3.44% |
| Deep Track Capital, LP | 2,018,005 | $50,006,000 | 3.29% |
| HighVista Strategies LLC | 118,778 | $2,943,000 | 1.78% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,917 | $158,000,000 | 1.65% |